Daily Newsletter

21 November 2023

Daily Newsletter

21 November 2023

Zevra Therapeutics completes Acer acquisition in $91m deal

Zevra has obtained access to Acer's rare disease assets Olpruva and Edsivo.

Vishnu Priyan November 21 2023

Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal.

The parties signed a definitive agreement for the merger in August 2023.

2.96 million shares of Zevra stock and contingent value rights (CVRs) were issued for Acer shares.

The CVRs represent the right to receive $76m to be paid to SWK Funding, Acer’s warrant holder, on meeting specific regulatory and net product sales milestones. 

Zevra also purchased Acer’s senior secured debt for $28.5m.

Zevra has obtained access to Acer's rare disease assets Olpruva, which is approved by the Food and Drug Administration (FDA) to treat specific urea cycle disorders, and Edsivo, currently being analysed in Phase III studies for vascular Ehlers-Danlos syndrome. 

The takeover will enhance the commercial and development expertise of Zevra through the addition of crucial personnel from Acer as well as its commercial systems.

Zevra Therapeutics president and CEO Neil McFarlane stated: “The acquisition marks an exciting milestone for Zevra as we advance our mission to deliver therapies to the rare disease community. 

“With our combined resources, expanded portfolio and expert capabilities, we have the opportunity to make a tremendous impact on the lives of people with serious rare diseases. We are excited about the opportunities ahead for patients and remain focused on executing our strategic priorities to create long-term shareholder value.”

Acute Renal Failure (ARF) - Market Landscape

Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials. While the current marketed drug space for ARF has only a handful of treatment options, currently available mid-to-late-stage pipeline drugs are likely to pave the way for a new treatment approach in the future.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close